Zobrazeno 1 - 10
of 164
pro vyhledávání: '"Peter D. Beitsch"'
Autor:
Mi Jeong Kwon, Sae Byul Lee, Jinil Han, Jeong Eon Lee, Jong Won Lee, Gyungyub Gong, Peter D Beitsch, Seok Jin Nam, Sei Hyun Ahn, Byung-Ho Nam, Young Kee Shin
Publikováno v:
PLoS ONE, Vol 13, Iss 11, p e0207155 (2018)
The Breast Cancer Test (BCT) score has been validated for its ability to predict the risk of distant metastasis in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. This study aimed to examine th
Externí odkaz:
https://doaj.org/article/598981f0399b476082fb17b5dbbf71ec
Autor:
Pat W. Whitworth, Peter D. Beitsch, Mary K. Murray, Paul D. Richards, Angela Mislowsky, Carrie L. Dul, James V. Pellicane, Paul L. Baron, Rakhshanda Layeequr Rahman, Laura A. Lee, Beth B. Dupree, Pond R. Kelemen, Andrew Y. Ashikari, Raye J. Budway, Cristina Lopez-Penalver, William Dooley, Shiyu Wang, Patricia Dauer, Andrea R. Menicucci, Erin B. Yoder, Christine Finn, Lisa E. Blumencranz, William Audeh
Publikováno v:
JCO precision oncology. 6
PURPOSE The prospective Neoadjuvant Breast Registry Symphony Trial compared the 80-gene molecular subtyping signature with clinical assessment by immunohistochemistry and/or fluorescence in situ hybridization in predicting pathologic complete respons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7552cc2eae44cbdfdcd52ffa6a663ea
https://pubmed.ncbi.nlm.nih.gov/36108259
https://pubmed.ncbi.nlm.nih.gov/36108259
Autor:
James V. Pellicane, Peter D. Beitsch, David T. Rock, Raye J. Budway, Carrie L. Dul, Pond R. Kelemen, Andrew Y. Ashikari, Paul L. Baron, Paul D. Weinstein, Angela Mislowsky, Laura A. Lee, Jennifer Beatty, Mary K. Murray, Beth B. Dupree, Christine Finn, Kate Corcoran, Shiyu Wang, Andrea R. Menicucci, Erin B. Yoder, Lisa E. Blumencranz, Patricia Dauer, William Audeh, Pat W. Whitworth
Publikováno v:
Surgical oncology. 45
As more patients with early-stage breast cancer receive neoadjuvant endocrine therapy (NET), there is a need for reliable biomarkers that can identify patients with HR+ HER2- tumors who are likely to benefit from NET. NBRST (NCT01479101) compared the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::786eb41bd3a6be7906097f03a2935026
https://pubmed.ncbi.nlm.nih.gov/36436423
https://pubmed.ncbi.nlm.nih.gov/36436423
Abstract PS8-30: Longitudinal clinical outcomes of a multi-center universal genetic testing registry
Autor:
Melissa Trudrung, Max Brown, Ian Grady, Barry P. Rosen, Mary Kay Hardwick, Rakesh Patel, Edward D. Esplin, Sarah M. Nielsen, Chloe Wernecke, Gia Compagnoni, Linsey Gold, Robert L. Nussbaum, Peter D. Beitsch, Richard J. C. Brown, Pat Whitworth
Publikováno v:
Cancer Research. 81:PS8-30
Background: Growing evidence indicates that restrictive criteria for determining eligibility of breast cancer patients for germline genetic testing (e.g. NCCN, etc.) can missa significant number who may benefit from testing. However, the clinical uti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0124818a2a1b473b0b27a5ae4d066a05
https://doi.org/10.1158/1538-7445.sabcs20-ps8-30
https://doi.org/10.1158/1538-7445.sabcs20-ps8-30
Autor:
Sarah M. Nielsen, Natalie Rickers, Emily Decker, Peter D. Beitsch, Hana Sroka, Ed D. Esplin, Robert L. Nussbaum, Alekhya Narravula, Pat Whitworth
Publikováno v:
Cancer Research. 81:PS8-14
Background:Therapeutic and risk management options have expanded for patients harboring pathogenic variants (PVs) in cancer predisposition genes. Historically, testing costs and clinical implementation challenges led to restrictive testing guidelines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::96e97ae6dd3113b65544ab4ca6a4cd64
https://doi.org/10.1158/1538-7445.sabcs20-ps8-14
https://doi.org/10.1158/1538-7445.sabcs20-ps8-14
Autor:
Pat W, Whitworth, Peter D, Beitsch, James V, Pellicane, Paul L, Baron, Laura A, Lee, Carrie L, Dul, Mary K, Murray, Mark A, Gittleman, Raye J, Budway, Rakhshanda Layeequr, Rahman, Pond R, Kelemen, William C, Dooley, David T, Rock, Kenneth H, Cowan, Beth-Ann, Lesnikoski, Julie L, Barone, Andrew Y, Ashikari, Beth B, Dupree, Shiyu, Wang, Andrea R, Menicucci, Erin B, Yoder, Christine, Finn, Kate, Corcoran, Lisa E, Blumencranz, William, Audeh
Publikováno v:
JCO Precision Oncology.
PURPOSE The 80-gene molecular subtyping signature (80-GS) reclassifies a proportion of immunohistochemistry (IHC)-defined luminal breast cancers (estrogen receptor–positive [ER+], human epidermal growth factor receptor 2–negative [HER2–]) as Ba
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ad8b84f487163f587594b6130e930c1
https://doi.org/10.1200/po.21.00463
https://doi.org/10.1200/po.21.00463
Autor:
Lynne Clark, Barbara L. Smith, Stephen E. Karp, Katherine Clegg Smith, Irene Wapnir, Sean Madden, Peter D. Beitsch, Stephanie A. Valente, W. David Lee, Donna Lynn Dyess, Nayana Dekhne, Beth-Ann Lesnikoski, Jorge Ferrer, Anees B. Chagpar, Peter W. Blumencranz, Kelly K. Hunt, David Carr, Brian Schlossberg, S Hwang, Linsey Gold, Daleela Dodge, Manna Chang, David B. Strasfeld
Publikováno v:
Cancer Research. 80:P1-20
Background: Standard surgical techniques result in positive lumpectomy margins 20-40% of the time. These positive margins require surgical re-excision which places significant burden on the healthcare system and patients. The LUM Imaging System consi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::778bc1e579253077978385feb41855b3
https://doi.org/10.1158/1538-7445.sabcs19-p1-20-06
https://doi.org/10.1158/1538-7445.sabcs19-p1-20-06
Autor:
Antonio Carlos Sánchez Ruiz, Laura Lee, Linsey Gold, Rakesh Patel, Paul L. Baron, Peter D. Beitsch, Pat Whitworth, Richard J. C. Brown
Publikováno v:
Cancer Research. 80:P2-16
Background: Molecular genomic profiles are increasingly used to guide treatment of refractory cancers and are on the forefront of personalized medicine for select patients. The neoadjuvant chemotherapy (NAC) setting provides a meaningful opportunity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1360c5e17b57dca9de20b2507e7b85a9
https://doi.org/10.1158/1538-7445.sabcs19-p2-16-21
https://doi.org/10.1158/1538-7445.sabcs19-p2-16-21
Autor:
Pat, Whitworth, Peter D, Beitsch, James V, Pellicane, Paul L, Baron, Laura A, Lee, Carrie L, Dul, Charles H, Nash, Mary K, Murray, Paul D, Richards, Mark, Gittleman, Raye, Budway, Rakhshanda Layeequr, Rahman, Pond, Kelemen, William C, Dooley, David T, Rock, Ken, Cowan, Beth-Ann, Lesnikoski, Julie L, Barone, Andrew Y, Ashikari, Beth, Dupree, Shiyu, Wang, Andrea R, Menicucci, Erin B, Yoder, Christine, Finn, Kate, Corcoran, Lisa E, Blumencranz, William, Audeh
Publikováno v:
Annals of surgical oncology.
The Neoadjuvant Breast Symphony Trial (NBRST) demonstrated the 70-gene risk of distant recurrence signature, MammaPrint, and the 80-gene molecular subtyping signature, BluePrint, precisely determined preoperative pathological complete response (pCR)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dee656e60d4074d0804e31bc2610da7e
https://pubmed.ncbi.nlm.nih.gov/35378634
https://pubmed.ncbi.nlm.nih.gov/35378634
Autor:
Pat W, Whitworth, Peter D, Beitsch, Rakesh, Patel, Barry, Rosen, Gia, Compagnoni, Paul L, Baron, Rache, Simmons, Eric A, Brown, Linsey, Gold, Dennis, Holmes, Linda Ann, Smith, Michael, Kinney, Ian, Grady, Patricia, Clark, Karen, Barbosa, Samuel, Lyons, Lee, Riley, Cynara, Coomer, Lisa, Curcio, Antonio, Ruiz, Sadia, Khan, Heather, MacDonald, Kevin, Hughes, Mary Kay, Hardwick, Brandie, Heald, Sandra B, Munro, Sarah M, Nielsen, Edward D, Esplin
Publikováno v:
JAMA Network Open. 5:e2232787
ImportanceNational Comprehensive Cancer Network guidelines currently recommend germline testing for high-risk genes in selected patients with breast cancer. The clinical utility of recommending testing all patients with breast cancer with multigene p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70642c7434ad41a62e1c31e6324c125a
https://doi.org/10.1001/jamanetworkopen.2022.32787
https://doi.org/10.1001/jamanetworkopen.2022.32787